Stocks · News reference
Lexicon Pharmaceuticals has announced the publication of new research detailing the biological effects of its drug candidate, sotagliflozin, in the context of cardiovascular disease.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lexicon Pharmaceuticals released baseline patient demographic data for its ongoing Phase 3 SONATA-HCM clinical trial evaluating sotagliflozin in patients with symptomatic hypertrophic cardiomyopathy.
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of sotagliflozin on platelet
Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time